• Liproxstatin-1 HCl: Precision Ferroptosis Inhibition in Dise

  2026-05-12

  Liproxstatin-1 HCl enables highly selective inhibition of ferroptosis, streamlining research in acute renal failure and hepatic ischemia/reperfusion injury. This article bridges the latest mechanistic insights—such as mitochondrial calcium’s role in GPX4 regulation—with actionable workflows, troubleshooting, and protocol optimizations for reproducible, high-impact ferroptosis assays.

• Anagliptin (SK-0403): Advanced DPP-4 Inhibition in Vascular

  2026-05-12

  Anagliptin (SK-0403) unlocks next-generation workflows for diabetes and cardiovascular research by targeting both DPP-4 inhibition and unique vasorelaxant pathways. Discover how APExBIO’s formulation streamlines experimental protocols, leverages Kv channel and SERCA pump modulation, and offers actionable troubleshooting for robust, reproducible results.

• Verteporfin (CL 318952): Optimizing Photodynamic and Autopha

  2026-05-11

  Verteporfin (CL 318952) offers dual-action versatility as both a potent photosensitizer for photodynamic therapy and a light-independent inhibitor of autophagy. This article delivers actionable protocols, troubleshooting strategies, and evidence-driven workflow enhancements for researchers targeting ocular neovascularization, apoptosis, and cell fate studies.

• Trypsin: Serine Protease Workflows for Cell Biology Success

  2026-05-11

  Trypsin (BA5744) from APExBIO delivers precise, high-solubility performance for proteolysis, cell culture, and specialized membrane fusion assays. This article dissects experimental workflows, advanced use-cases, and troubleshooting strategies to maximize research outcomes in cell proliferation, wound healing, and viral fusion studies.

• M344: Histone Deacetylase Inhibitor for Neuroblastoma Resear

  2026-05-10

  M344 stands out as a potent, cell-permeable histone deacetylase inhibitor with submicromolar efficacy and superior tumor-suppressive performance in aggressive pediatric cancers. Its robust acetylation-driven mechanisms and validated protocols empower researchers to design reproducible workflows for cell differentiation, proliferation inhibition, and apoptosis assays across neuroblastoma and breast cancer models.

• Weight Loss Restores Intestinal Stretch-Mediated Satiety in

  2026-05-09

  This paper demonstrates that intestinal stretch acutely suppresses food intake and improves glucose tolerance through mechanisms independent of classical incretin hormone signaling. Obesity impairs this response, but both dietary and surgical weight loss restore it, providing new insight into the physiology of satiety and metabolic regulation.

• HyperScript III RT SuperMix: Raising the Bar in cDNA Precisi

  2026-05-08

  Discover how HyperScript III RT SuperMix for qPCR (with gDNA wiper) sets new standards for accurate gene expression analysis, especially for challenging high-GC and low-input RNA. This article bridges molecular subtyping insights with practical assay optimization for translational and clinical research.

• Synergistic CDK4/6 and BET Inhibition in Pancreatic Cancer M

  2026-05-08

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth, reversing the pro-metastatic effects of CDK4/6 inhibition alone by modulating the GSK3β-mediated Wnt/β-catenin pathway. This work provides a mechanistic rationale and experimental framework for combinatorial targeting in aggressive PDAC subtypes.

• A20 Suppresses Oxidized Self-DNA Inflammation in Acute Kidne

  2026-05-07

  This study elucidates how the ubiquitin-editing enzyme A20 and its derived peptide mitigate inflammation in acute kidney injury (AKI) by inhibiting NLRP3 inflammasome-driven pyroptosis triggered by oxidized self-DNA. The findings reveal a novel regulatory mechanism with translational implications for targeting sterile inflammation in renal and potentially other tissue injuries.

• (R,S)-Anatabine: Advancing Translational Neurodegeneration R

  2026-05-07

  This thought-leadership article explores the mechanistic foundations and translational strategy for leveraging (R,S)-Anatabine in Alzheimer's disease research. Integrating recent evidence on amyloid-beta pathway modulation and inflammation, the piece provides actionable guidance for researchers, distinguishes APExBIO's offering, and contextualizes these advances within the evolving landscape of precision neurotherapeutics.

• Weight Loss Restores Intestinal Stretch-Mediated Satiety in

  2026-05-06

  This study demonstrates that intestinal stretch acutely suppresses food intake and improves glucose tolerance—effects that are blunted in obesity but restored after weight loss via diet or surgery. These findings highlight a GLP-1 independent mechanism of metabolic regulation and provide a foundation for new approaches to type II diabetes treatment research.

• Adefovir-Induced Osteochondrosis Mimicking Ankylosing Spondy

  2026-05-06

  This case study demonstrates that long-term adefovir therapy can induce hypophosphatemic osteochondrosis, presenting with clinical and imaging features that closely mimic ankylosing spondylitis (AS). The work underscores the importance of biochemical assessment in differential diagnosis, especially in patients on nucleotide analog antivirals.

• FK866 (APO866): NAMPT Inhibition in Hematologic Cancer Resea

  2026-05-05

  FK866 (APO866) is a potent, non-competitive NAMPT inhibitor that selectively depletes NAD in hematologic cancer cells, particularly acute myeloid leukemia (AML). Its caspase-independent mechanism and in vivo efficacy underpin its central role in modern NAD metabolism research.

• Resveratrol Inhibits EMT in Glioblastoma via Smad Signaling

  2026-05-05

  This study demonstrates that resveratrol suppresses epithelial-mesenchymal transition (EMT) and reduces stem cell-like properties in glioblastoma (GBM) by inhibiting TGF-β1-induced Smad-dependent signaling. These findings provide mechanistic insight into EMT regulation and highlight potential strategies for targeting GBM invasiveness.

• Adefovir-Induced Hypophosphatemic Osteochondrosis Mimicking

  2026-05-04

  This article analyzes a case report in which long-term adefovir therapy for hepatitis B virus led to hypophosphatemic osteochondrosis, closely imitating the clinical and imaging features of ankylosing spondylitis (AS). The findings underscore the importance of differential diagnosis in HBV-treated patients presenting with musculoskeletal symptoms, and illustrate the unique diagnostic pitfalls associated with nucleotide analog antivirals.

15780 records 1/1052 page Next 12345 下5页 Last page